RNA methylation modification refers to the process in which methyl groups are added to nucleotides under the mediation of RNA methyltransferases. m6A, a prevalent form of RNA methylation in eukaryotes, is one of the most common types of RNA methylation modifications, characterized by the addition of a methyl group to the N6 position of adenine. Abundant research has shown that m6A modification plays a crucial role in regulating RNA processing, splicing, nuclear export, translation, stability, and even phase separation, which is essential for the development of various human diseases. Besides its vital role in normal hematopoiesis, central nervous system development, and reproductive system development, aberrant m6A modification has also been implicated in various types of human cancers. Additionally, increasing evidence suggests that m6A modification is closely associated with the occurrence and progression of cardiovascular diseases such as cardiac hypertrophy, heart failure, ischemic heart disease, and pulmonary arterial hypertension. The level of m6A modification is a dynamic reversible process regulated by methyltransferases (writers) and demethylases (erasers). Methyltransferases exert their function through a complex composed of multiple proteins, including methyltransferase-like protein 3 (METTL3), METTL14, METTL16, RNA-binding motif protein 15 (RBM15) and its homolog RBM15B, zinc finger CCCH domain-containing protein 13 (ZC3H13), vir-like m6A methyltransferase associated protein (VIRMA, also known as KIAA1429), and Wilms tumor 1-associated protein (WTAP), which transfer methyl groups from the donor S-adenosyl methionine (SAM) to adenine. Among them, METTL3, METTL14, and WTAP are the core members of this complex.
Schematic diagram of RNA modification types.
Subsequently, m6A methylation is recognized by m6A reader proteins such as the YTH domain family proteins (YTHDF1, 2, 3), insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs), and heterogeneous nuclear ribonucleoprotein (HNRNP) family proteins. The reversible process of m6A demethylation is executed by erasers such as fat mass and obesity-associated protein (FTO) and ALKB homolog 5 (ALKBH5).
*Related Services from BOC RNA
RNA methylation modifications account for over 60% of all RNA modifications, and N6-methyladenosine (m6A) is the most prevalent modification on mRNA and lncRNAs in higher organisms. Currently, m6A modifications have been found to occur on microRNAs, circRNAs, rRNAs, tRNAs, and snoRNAs. m6A modification primarily occurs on adenine within the RRACH sequence, and its function is determined by "writers," "erasers," and "readers." The "writer" refers to the methyltransferase complex, known components of which include METTL3, METTL14, WTAP, and KIAA1429. ALKBH5 and FTO act as demethylases (erasers) to reversibly remove methyl groups. m6A is recognized by m6A-binding proteins, with known "reader" proteins including YTH domain proteins (including YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2) and the heterogeneous nuclear ribonucleoprotein (HNRNP) family (HNRNPA2B1 and HNRNPC).
A class of proteins containing YTH domain function has been identified as m6A-modified binding proteins. Among them, YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2 have been confirmed as m6A-binding proteins. YTHDF1 mainly affects the translation of m6A-modified genes, YTHDF2 mainly affects the degradation of m6A-modified genes, and YTHDC1 binds to m6A-modified genes to affect their splicing. HNRNPC is a rich nuclear RNA-binding protein involved in pre-mRNA processing, and studies have shown that HNRNPC regulates the abundance and selective splicing of target transcripts through m6A-RNA binding.
RNA m6A modification plays a significant role in the regulation of gene expression, and abnormalities in its regulatory mechanisms may be associated with human diseases or cancer. Currently, it has been found that m6A may affect sperm development (ALKBH5, METTL3, Ythdc2), development (METTL3, FTO, ALKBH5), immunity (METTL3), UV-induced DNA damage response (METTL3, FTO), tumor initiation (YTHDF2), or metastasis (METTL14), stem cell renewal (METTL14), adipocyte differentiation (FTO), circadian rhythm, cell development differentiation, cell division, and other life processes.